Compass Therapeutics announced positive Phase 2/3 trial results for tovecimig, showing significant improvement in progression-free survival and overall response rate for biliary tract cancer patients. The drug received Orphan Drug Designation and the company plans a BLA submission later this year. Additionally, Phase 1 studies for CTX-8371 and CTX-10726 bispecific antibodies are progressing, with data presentations expected in 2026. The company holds $195 million in cash, supporting operations into 2028.
The FDA has granted traditional approval to Fabhalta (iptacopan), a first-in-class complement inhibitor, for slowing kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN). Fabhalta showed a 48% slower decline in kidney fu...
Corbin Advisors' Q2 2026 survey shows industrial investor sentiment at its highest in five years, with 84% of participants bullish or neutral-to-bullish due to strong order momentum and demand from data centers and AI sectors. Expectations for Q2 rev...
IPG Photonics announced a binding offer to acquire Lumibird Medical for €300 million, with an additional earnout of up to €50 million based on performance. This acquisition will expand IPG's Advanced Solutions portfolio in medical lasers, particularl...
Oil prices increased as tensions escalated between the US and Iran, with Iran threatening to retaliate against regional infrastructure if the US strikes its key facilities. US West Texas Intermediate futures rose 1.32% to $80.09 per barrel, while Bre...
Venezuela's USDT stablecoin trading volume has reached about 75% of its monthly oil export value, reflecting the country's shift to a parallel financial system amid economic sanctions and hyperinflation. The state oil company PDVSA requires prepaymen...
